AbstractsBiology & Animal Science

Influenza specific T- and B-cell responses in immunosuppressed patients

by Aditya Sai Ambati

Institution: Karolinska Institute
Year: 2015
Record ID: 1329727
Full text PDF: http://hdl.handle.net/10616/44577


Influenza, known as the ‘flu’, is a recurrent acute viral infection that might cause severe inflammation, particularly in vulnerable individuals, i.e. young children, the elderly, and immune-suppressed patients, such as stem cell transplant recipients. Prevention strategies, primarily vaccination, and possibly the use of anti-viral drugs, are recommended with the aim to reduce mortality and morbidity. Influenza vaccination responses are often sub-optimal in immune-compromised patients. There is therefore a need to evaluate other vaccination systems and schedules to improve vaccine efficacy. We mapped the humoral and cellular anti-flu directed immune responses and studied in a first set of experiments the immune responses in immune competent individuals prior to, and following a natural pandemic influenza infection, as well as after adjuvanted Pandemrix® influenza vaccination. This was performed prospectively during the H1N1 pandemic influenza of 2009. ‘High content’ influenza proteome peptide arrays were used to gauge serum IgG epitope signatures prior to and after Pandemrix® vaccination/ or H1N1 pandemic infection described in paper I. A novel epitope residing in the sialic acid receptor-binding domain of VEPGDKITFEATGNL (251-265) of the pandemic flu hemagglutinin was identified. This epitope was found to be exclusively recognized in serum from previously vaccinated individuals and never in serum from individuals with H1N1 infection. The natural H1N1 infection induced a different footprint of IgG epitope recognition patterns as compared to the Pandemrix® H1N1 vaccination. Pre-transplant influenza vaccination of the donor or allogeneic hematopoietic stem cell (HSCT) candidate was evaluated in a randomized study of 122 HSCT patients reported in paper II. The antibody titers against H1 (p=0.028) and H3 (p<0.001) were highest in the pretransplant recipient vaccination group until d.180 after transplantation. A significant difference was found concerning the specific Ig levels against pandemic H1N1 at 6 months after HSCT (p=0.02). The mean IgG levels against pandemic H1N1, generic H1N1 and H3N2 were highest in the pre-transplant recipient vaccination group. Pre-transplant influenza vaccination of the donor or the HSCT candidate was found to be beneficial in eliciting seroprotective titers. The immunogenicity after a single dose of adjuvanted trivalent virosomal vaccination was evaluated in a cohort of 21 HSCT recipients and compared to a control cohort of 30 HSCT recipients who received a single dose of non-adjuvanted seasonal trivalent subunit vaccination, reported in Paper III. The delta change of IFNγ production in response to pandemic influenza H1N1 (p=0.005) and influenza B antigens (p=0.01) were significantly increased in blood from individuals who received the virosomal, as compared to the nonadjuvanted vaccine. Virosomal vaccination was found to be beneficial in eliciting robust cellular immune responses to influenza pandemic H1N1. Pandemic influenza hemagglutinin MHC class 1 peptide restricted CD8…